Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC

Table 1

Clinical and disease characteristics of patients included in the study.

Patient	Age	Gender	Additional metastatic sites (not including brain)	Molecular aberration	Time to symptomatic BM (months)	BM symptoms	BM number/characteristics
1	59	Female	LN, liver, bone, adrenal	ALK rearrangement	33	Aphasia, headache	>10, LMD
2	62	Female	Lung, LN	EGFR L747S mutation	22	Gait disturbance, N/V	>10, LMD
3	78	Female	Lung, LN	EGFR L858R mutation	73	Headache, seizure	7
4	75	Female	Lung, liver, bone, adrenal	EGFR exon 19 deletion	0	Confusion	4, LMD
5	82	Female	Bone	EGFR L858R mutation	0	Confusion, cognitive decline	LMD
6	72	Male	LN, liver, bone	EGFR exon 19 deletion	0	N/V	>10, LMD
7	51	Female	None	EGFR exon 19 deletion	0	Gait disturbance, N/V, dizziness	3
8	85	Female	Adrenal	EGFR exon 19 deletion	0	Dizziness	LMD
9	55	Female	Lung, adrenal	EGFR L861Q mutation	0	Headache, N/V, confusion, vision loss	>10

BM: brain metastases; LN: lymph nodes; ALK: anaplastic lymphoma kinase; EGFR: epidermal growth factor receptor; N/V: nausea and vomiting; LMD: leptomeningeal disease.